samedan logo

 
 
spacer
home > ict > summer 2019 > the landscape of clinical approval
PUBLICATIONS
International Clinical Trials

The Landscape of Clinical Approval





Cell and gene therapies, and other advanced medicinal products, have generated substantial public health interest, and deservedly so. These living drugs have shown remarkable effectiveness against cancer and other life-threatening illnesses, including rare diseases with previously no treatment available. Recent approvals of cell- and gene-based therapies underscore the industry’s conviction that these drugs will have a strong, positive impact on patient health (1-2). At the same time, accelerated approval pathways are placing a heavy onus on drug developers to assure a consistently pure and efficacious product. Sourcing donor material and assuring efficacy are a lot more complicated when a drug comprises living cells and tissues rather than synthetic products. Accelerated approval also puts significant strain on starting material suppliers, especially in the cell therapy space.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the authors


Dominic Clarke PhD has 15-plus years of experience developing enabling solutions for cell therapy and bioprocessing applications. Dominic is the Global Head of Cell Therapy at HemaCare, the leading provider of donor starting material for development and commercial cell and gene therapies, where he is actively engaged with industry experts to ensure the highest quality materials are delivered. Previously, he has held roles as the Global Product Manager for Charter Medical's cell therapy and bioprocessing disposables portfolio, focused on creating flexible closedsystem solutions for early- and late-stage production, and as the Director of Research and Development at BioLife Solutions, developing novel biopreservation media and methods to support extended stability of cells and tissues.



Brad N Taylor PhD is the Global Marketing Director at HemaCare. Brad has 13- plus years of experience in the biotech industry, addressing multiple aspects of drug discovery and preclinical development. Previously, he has held roles as Application Scientist and Product Manager in the In Vivo Imaging division of PerkinElmer, where he worked to bring innovative solutions to market to assist the research community in expediting and streamlining the process of preclinical drug discovery for cancer and other clinical applications in animal models of disease.


Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement